Search | OpenScholar

Search results

812 results found

Nociceptive pulmonary-cardiac reflexes are altered in the spontaneously hypertensive rat.

Publication: Journal Article

Hooper, Shane, Katherine R Stanford, Pierina A Alencar, Natascha G Alves, Jerome W Breslin, Jay B Dean, Kendall F Morris, and Thomas E Taylor-Clark. 2019. “Nociceptive Pulmonary-Cardiac Reflexes Are Altered in the Spontaneously Hypertensive Rat.”. The Journal of Physiology 597 (13): 3255-79.

Sphingosine-1-Phosphate Reduces Hemorrhagic Shock and Resuscitation-Induced Microvascular Leakage by Protecting Endothelial Mitochondrial Integrity.

Publication: Journal Article

Alves, Natascha G, Andrea N Trujillo, Jerome W Breslin, and Sarah Y Yuan. 2019. “Sphingosine-1-Phosphate Reduces Hemorrhagic Shock and Resuscitation-Induced Microvascular Leakage by Protecting Endothelial Mitochondrial Integrity.”. Shock (Augusta, Ga.) 52 (4): 423-33.

for the P2B Study Group. Double-Blind Study comparing P2B001 (combination of low-doses of extended-release Pramipexole and Rasagiline) to components and to optimised doses of Pramipexole-extended release in early Parkinson’s Disease.

Publication: Journal Article

Hauser, RA, CW Olanow, D Burdick, R Dhall, JA de Marcaida, RA Gil, DL Kreitzman, L Elmer, A McGarry, and K Kieburtz. 2024. “For the P2B Study Group. Double-Blind Study Comparing P2B001 (combination of Low-Doses of Extended-Release Pramipexole and Rasagiline) to Components and to Optimised Doses of Pramipexole-Extended Release in Early Parkinson’s Disease.”. . Mov Disord. 2024 Feb;39(2):350-359. Doi: 10.1002/Mds.29642. Epub 2023 Oct 27. PMID: 37886872.

Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance.

Publication: Journal Article

Fung, VSC, J Aldred, MP Arroyo, F Bergquist, RA Hauser, M Bouchard, S Bray, et al. 2024. “Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion for the Treatment of Motor Fluctuations in Parkinson’s Disease: Considerations for Initiation and Maintenance.”. . Clin Park Relat Disord. 2024 Feb 10;10:100239. Doi: 10.1016/J.prdoa.2024.100239. ECollection 2024. PMID: 38419617.

OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2.

Publication: Journal Article

Hauser, RA, A Videnovic, P Soares-da-Silva, GS Liang, K Olson, E Jen, JF Rocha, and O Klepitskaya. 2024. “OFF-Times Before, During, and After Nighttime Sleep Periods in Parkinson’s Disease Patients With Motor Fluctuations and the Effects of Opicapone: A Post Hoc Analysis of Diary Data from BIPARK-1 and -2.”. Parkinsonism Relat Disord. 2024 Jun;123:106971. Doi: 10.1016/J.Parkreldis.2024.106971. Epub 2024 Apr 9.PMID: 38631081 .

Insulin-like growth factor 1 reduces coronary atherosclerosis in pigs with familial hypercholesterolemia

Publication: Journal Article

Sukhanov, S., Y. Higashi, T. Yoshida, S. Danchuk, M. Alfortish, TT. Goodchild, A. Scarborough, and TE. Sharp. 2023. “Insulin-Like Growth Factor 1 Reduces Coronary Atherosclerosis in Pigs With Familial Hypercholesterolemia”. JCI Insight.

Members of the IPMDS Rating Scales Review Committee. Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. 2023 Jun;38(6):1008-1026. doi: 10.1002/mds.29392. Epub 2023 Apr 20. PMID: 37081740

Publication: Journal Article

Martino, D, V Karnik, R Bhidayasiri, DA Hall, RA Hauser, A Macerollo, TM Pringheim, et al. 2023. “Members of the IPMDS Rating Scales Review Committee. Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. 2023 Jun;38(6):1008-1026. Doi: 10.1002/Mds.29392. Epub 2023 Apr 20. PMID: 37081740”. Mov Disord.

Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment. Neurol Ther. 2022 Mar;11(1):459-469. doi: 10.1007/s40120-021-00317-5. Epub 2022 Feb 2. PMID: 35107750.

Publication: Journal Article

Hauser, RA, A Favit, LA Hewitt, A Lindsten, S Gomy, S Kymes, and SH Isaacson. 2022. “Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment. Neurol Ther. 2022 Mar;11(1):459-469. Doi: 10.1007/S40120-021-00317-5. Epub 2022 Feb 2. PMID: 35107750.”. Neurol Ther.

P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease. Adv Ther. 2022 May;39(5):1881-1894. doi: 10.1007/s12325-022-02097-2. Epub 2022 Mar 10. PMID: 35267155.

Publication: Journal Article

Hauser, RA, N Giladi, W Poewe, J Brotchie, H Friedman, S Oren, and P Litman. 2022. “P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease. Adv Ther. 2022 May;39(5):1881-1894. Doi: 10.1007/S12325-022-02097-2. Epub 2022 Mar 10. PMID: 35267155.”. Adv. Ther.

Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study. 2022 Feb 23;13:773999. doi: 10.3389/fneur.2022.773999. eCollection 2022. PMID: 35280262.

Publication: Journal Article

Hauser, RA, H Barkway, HH Fernandez, SA Factor, J Jimenez-Shahed, N Gross, L Marinelli, et al. 2022. “Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study. 2022 Feb 23;13:773999. Doi: 10.3389/Fneur.2022.773999. ECollection 2022. PMID: 35280262.”. Front Neurol.